The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: Current status

Stem Cells

Volumn 18, Issue 3, 2000, Pages 166-175

  Papamichael, D ^a  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

Author keywords

5 Fluorouracil; Capecitabine; MTA; Raltitrexed; S 1; Thymidylate synthase; UFT

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NOLATREXED; OXALIPLATIN; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR; UFT;

CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; META ANALYSIS; REVIEW;

EID: 0034089447     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-3-166     Document Type: Review

References (72)

1. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993;29A:2077-2079.
2. Allen-Mersh TG, Earlam S, Fordy C et al. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-1260.
3. Glimelius B, Hoffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6:267-274.
4. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904-911.
5. Scheithauer W, Rosen H, Kornek G-V et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993;306:752-755.
6. Danenberg PV, Danenberg KD. Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978;17:4018-4024.
7. Sand DV, McHenry CS, Sommer H et al. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471-481.
8. Heidelberger C, Chaudhari NK, Danenberg P et al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 1957;179:663-666.
9. Sobrero AF, Aschele C, Bertino JR et al. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-381.
10. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-507.
11. Horton J, Olson KB, Sullivan J et al. 5-Fluorouracil in cancer: an improved regimen. Ann Intern Med 1970;73:897-905.
12. Shah A, McDonald W, Goldie J et al. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep 1985;69:739-742.
13. Lokich J. Infusional 5-FU for advanced colorectal cancer. Int J Dent Symp 1995;5:208-211.
14. Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995;13:297-302.
15. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
16. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
17. Rustum YF, Cao S, Zhang Z et al. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. The Cancer Journal 1998;4:12-18.
18. The Advanced Colorectal Meta-analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-969.
19. Hill M, Norman A, Cunningham D et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995;13:2317-2323.
20. Greco FA, Figlin R, York M et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996;14:2674-2681.
21. Kosmidis PA, Tsavaris N, Skarlos D et al. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 1996;14:2682-2687.
22. Seymour MT, Slevin ML, Kerr DJ et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 1996;14:2280-2288.
23. Wadler S. Antineoplastic activity of the combination of 5-fluorouracil and interferon: preclinical and clinical results. Semin Oncol 1992;19(suppl 4):38-40.
24. Gamelin E, Boisdron-Celle M, Guerin-Meyer V et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105-1110.
25. Harris BE, Song R, Soong S-J et al. Relationship of dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for arcadian variation of 5-fluorouracil levels in cancer patients receiving protracted continuous infusion. Cancer Res 1990;50:197-201.
26. Harris BE, Carpenter JT, Diasio RB et al. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991;68:499-501.
27. Baccanari DP, Davis ST, Knick VC et al. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumour efficacy of 5-Fluorouracil. Proc Natl Acad Sci USA 1993;90:11064-11068.
28. Cao S, Rustum YM, Spector T et al. 5-Ethinyluracil (776C85) modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507-1510.
29. Ahmed FY, Johnston SJ, Cassidy J et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumours. J Clin Oncol 1999;17:2439-2445.
30. Schilsky RL, Burris H, Ratain M et al. Phase I clinical and pharmacologic study of 776C85 plus 5-fluorouracil in patients with advanced cancer. Proc Am Soc Clin Oncol 1996;15:485a.
31. Baker SD, Khor SP, Adjei AA et al. Pharmacokinetics, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85. J Clin Oncol 1996;14:3085-3096.
32. Mani S, Beck T, Chevlen E et al. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998;17:281a.
33. Peters GJ, Laurensse E, Leyva A et al. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986;46:20-28.
34. Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur J Cancer 1980;16:427-432.
35. Nio Y, Kimura H, Tsubono M et al. Antitumor activity of 5′-deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tissues from human digestive organs. Anticancer Res 1992;12:1141-1146.
36. El Sayed YM, Sadee W. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. Cancer Res 1983;43:4039-4044.
37. Tuchman M, Ramnaraine ML, O'Dea RF et al. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res 1985;45:5553-5556.
38. Uchida J, Takeda S, Kawaguchi Y et al. Selective antitumour effect of UFT, a drug composed of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Proc Am Assoc Cancer Res 1991;32:417a.
39. Ota K, Taguchi T, Kimura K et al. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22:333-338.
40. Carulla J, Bellmunt J, Sole LA et al. A randomized trial of CDDP plus 5FU in continuous infusion, in locally advanced squamous cell carcinoma of head and neck, ECCO-4. Proc Fourth Eur Conf Clin Oncol 1987;247a.
41. Villalon AH, De Guzman LB, Samson MC et al. A randomized trial of oral UFT (tegafur+uracil) and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer at the Philippine General Hospital. Proc Am Soc Clin Oncol 1997;16:197a.
42. Pazdur R, Covington WP, Brown NS et al. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil. Proc Am Soc Clin Oncol 1996;15:474a.
43. Carmichael J, Popiela D, Radstone S et al. Randomized comparative study of Orzel plus leucovorin versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:263a.
44. Pazdur R, Douillard J-Y, Skillings JR et al. Multicenter phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:263a.
45. Seymour MT, Dent JT, Papamichael D et al. Epirubicin, cisplatin and oral UFT: an active and convenient regimen in upper gastrointestinal cancer. Proc Am Soc Clin Oncol 1998;17:259a.
46. Ishikawa T, Sawada N, Segikuchi F et al. Xeloda (capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Am Soc Clin Oncol 1997;16:226a.
47. Findlay M, Van Cutsem E, Kocha W et al. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997;16:227a.
48. Twelves C, Harper P, Van Cutsem E et al. A phase III trial (S014796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:263a.
49. Cox JV, Pazdur R, Thibault A et al. A phase III trial of xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:265a.
50. Horikoshi N, Mitachi Y, Sakata Y et al. S-1, a new oral fluoropyrimidine, is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996;15:206a.
51. Rustum YM, Cao S, Shiraska T et al. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model systems, active in clinical trials. Proc Am Soc Clin Oncol 1997;16:227a.
52. Jackman AL, Farrugia DC, Gibson W et al. ZD1964 (Tomudex): a new thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Eur J Cancer 1995;31A:1277-1282.
53. Cunningham D. Zalcberg J, Smith I et al. "Tomudex" (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. "Tomudex" International Study Group. Ann Oncol 1996;7:179-182.
54. Cunningham D, Zalcberg JR, Rath U et al. Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996;7:961-965.
55. Pazdur R, Vincent M. Raltitrexed versus 5-Fluorouracil and leucovorin in patients with advanced colorectal cancer: results of a randomized multicentre North American trial. Proc Am Soc Clin Oncol 1997;16:228a.
56. Harper P on behalf of the Tomudex study group. Advanced colorectal cancer: results from the latest raltitrexed (Tomudex) comparative study. Proc Am Soc Clin Oncol 1997;16:228a.
57. De Gramont A, Krulik M, Cady J et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-1503.
58. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-432.
59. Maughan TS, James RD, Kerr D et al. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (deGramont, Lokich and raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:262a.
60. Rafi R, Boddy AV, Cavete JA et al. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Oncol 1998;16:1131-1141.
61. Belani CP, Lembersky B, Ramanathan R et al. A phase II trial of Thymitaq (AG337) in patients with adenocarcinoma of the colon. Proc Am Soc Clin Oncol 1997;16:272a.
62. Loh K, Stuart K, Cohn A et al. A phase II trial of Thymitaq (AG337) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 1997;16:265a.
63. Rinaldi DA, Burris HA, Dorr FA et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-2850.
64. Cripps MC, Burnell M, Jolivet J et al. Phase II study of a multi-targeted antifolate (LY231514)(MTA) as first line therapy in patients with locally advanced or metastatic colorectal cancer. Eur J Cancer 1997;33:8172.
65. John W, Picus J, Blanke C. Activity of MTA (LY231514) in patients with advanced colorectal cancer - results of a phase II study. Proc Am Soc Clin Oncol 1998;18:277a.
66. Jackman AL, Kimbell R, Brown M et al. The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv Exp Med Biol 1994;370:185-188.
67. Cunningham D. Current status of colorectal cancer: CPT-II (irinotecan), a therapeutic innovation. Eur J Cancer 1996;32A:S1-S8.
68. Soulie P, Raymond E, Brienza S et al. Oxaliplatin: the first DACH platinum in clinical practice. Bull Cancer 1997;84:665-673.
69. de Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-219.
70. Rothenberg ML, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-1135.
71. de Gramont A, Figer A, Seymour M et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998;17:985a.
72. Douillard JY, Cunningham D, Roth AD. A randomized phase III trial comparing irinotecan + 5FU/folinic acid to the same schedule of 5FU/FA in patients with metastatic colorectal carcinoma as front line chemotherapy. J Clin Oncol 1999;18:233a.